CAS 194423-06-8: N-[4-[(3-Bromophenyl)amino]-6-quinazolinyl]-2-butynamide
Formula:C18H13BrN4O
InChI:InChI=1S/C18H13BrN4O/c1-2-4-17(24)22-14-7-8-16-15(10-14)18(21-11-20-16)23-13-6-3-5-12(19)9-13/h3,5-11H,1H3,(H,22,24)(H,20,21,23)
InChI key:InChIKey=BTYYWOYVBXILOJ-UHFFFAOYSA-N
SMILES:O=C(C#CC)NC=1C=CC2=NC=NC(NC=3C=CC=C(Br)C3)=C2C1
- Synonyms:
- N-[4-[(3-Bromophenyl)amino]-6-quinazolinyl]-2-butynamide
- 2-Butynamide, N-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-
- EKI 785
- CL 387785
- WAY-EKI 785
![discount label](https://static.cymitquimica.com/public/img/discount.png)
2-ButynaMide, N-[4-[(3-broMophenyl)aMino]-6-quinazolinyl]-
CAS:194423-06-8
Formula:
C18H13BrN4O
Purity:
98%
Color and Shape:
Solid
Molecular weight:
381.2260
Ref: IN-DA00ABJJ
2mg | 49.00 € | ||
5mg | 75.00 € | ||
10mg | 102.00 € | ||
25mg | 110.00 € |
Estimated delivery in United States, on Monday 3 Mar 2025
![discount label](https://static.cymitquimica.com/public/img/discount.png)
CL-387785
CAS:194423-06-8
Formula:
C18H13BrN4O
Purity:
>98.0%(GC)
Color and Shape:
White to Light yellow powder to crystal
Molecular weight:
381.23
Ref: 3B-C3575
25mg | 138.00 € | ||
100mg | 368.00 € |
Estimated delivery in United States, on Tuesday 4 Mar 2025
![discount label](https://static.cymitquimica.com/public/img/discount.png)
CL-387785
CAS:194423-06-8
CL-387785 is an irreversible EGFR inhibitor with IC50 of 370 pM; overcomes T790M mutation resistance.
Formula:
C18H13BrN4O
Purity:
96.68% - 98.09%
Color and Shape:
Solid
Molecular weight:
381.23
Ref: TM-T2245
5mg | 39.00 € | ||
10mg | 58.00 € | ||
25mg | 105.00 € | ||
50mg | 169.00 € | ||
100mg | 264.00 € | ||
200mg | 373.00 € | ||
1mL*10mM (DMSO) | 44.00 € |
Estimated delivery in United States, on Monday 10 Mar 2025
![discount label](https://static.cymitquimica.com/public/img/discount.png)
CL 387785
CAS:194423-06-8
Irreversible inhibitor of EGFR receptor
Formula:
C18H13BrN4O
Purity:
Min. 95%
Molecular weight:
381.23 g/mol
Ref: 3D-FC29856
5mg | 348.00 € | ||
10mg | 462.00 € | ||
25mg | 784.00 € |
Estimated delivery in United States, on Monday 14 Apr 2025